In a significant step forward for public health, the World Health Organization (WHO) has approved the first malaria treatment specifically designed for infants. This groundbreaking development, known as Coartem Baby, will enable safe and effective treatment for newborns, addressing a critical gap in malaria care and potentially saving countless young lives.
A Major Public Health Breakthrough
Malaria remains a leading cause of illness and death among children in sub-Saharan Africa. Recent statistics reveal that approximately 18% of infants under six months old in some African regions are infected with this life-threatening disease. Tragically, in 2024 alone, malaria accounted for around 610,000 fatalities, with a staggering three-quarters of those victims being children under the age of five.
Historically, infants diagnosed with malaria have been treated with formulations intended for older children, which can lead to serious risks, including dosing errors, side effects, and toxicity. The introduction of Coartem Baby—administered as sweet cherry-flavoured tablets that can be easily dissolved in liquids like breast milk—represents a pivotal advancement in ensuring that even the youngest patients receive appropriate care.
Dr. Tedros Adhanom Ghebreyesus, WHO Director-General, emphasised the transformative potential of this new treatment: “For centuries, malaria has stolen children from their parents, and health, wealth, and hope from communities. But today, the story is changing.”
Coartem Baby: Designed for the Smallest Patients
Coartem Baby combines two effective antimalarial agents, artemether and lumefantrine, and is specifically formulated for infants weighing as little as 2 kg (approximately 4.4 lb). This targeted approach addresses the unique needs of newborns, countering the outdated belief that infants are largely immune to the disease due to maternal antibodies.
Dr. Martin Fitchet, Chief Executive of the Medicines for Malaria Venture (MMV), hailed the WHO’s prequalification of Coartem Baby as a “major public-health milestone.” This designation signifies that the treatment meets rigorous international standards of quality, safety, and efficacy, paving the way for procurement by public health systems in malaria-endemic countries, particularly in sub-Saharan Africa.
The initial rollout of Coartem Baby has already commenced in Ghana, where eight-month-old Baby Wonder was one of the first to receive the treatment. At just 12 weeks old, he was hospitalised with a high fever, and tests confirmed the presence of malaria parasites in his bloodstream. His mother, Naomi, expressed her fears, especially since he was born underweight. Fortunately, thanks to the coordination of local doctors, Baby Wonder is now healthy and thriving.
A New Hope for Healthcare Providers
The introduction of Coartem Baby offers renewed hope not only for affected infants and their families but also for healthcare professionals who have struggled to treat malaria in the youngest patients. Dr. Emmanuel Aidoo, a paediatrician at Methodist Hospital in Ankaase, Ghana, noted the challenges faced in diagnosing and treating malaria in newborns. He stated, “As doctors, we have tended to look for malaria in older children, but when newborn babies got sick, nobody seemed to know what to do. Having a new treatment tailor-made for infants that is well tolerated gives us confidence.”
Novartis, the pharmaceutical company behind the development of Coartem Baby, has committed to distributing the treatment on a largely not-for-profit basis in regions where malaria is endemic, ensuring that financial barriers do not hinder access to this vital medication.
Why it Matters
The approval of Coartem Baby represents a landmark achievement in the fight against malaria, particularly for the most vulnerable—newborns and infants. By providing a safe and effective treatment option for this demographic, healthcare systems can significantly reduce the incidence of severe malaria cases and fatalities. This development not only highlights the importance of tailored medical interventions for children but also reinforces the global commitment to combat this devastating disease. As countries continue to grapple with the challenges posed by malaria, innovations like Coartem Baby could be instrumental in reshaping the future of child health and survival in malaria-endemic regions.
